Products - Autoimmune - Endocrinology - Thyroid diseases

Thyroid diseases

Contact our Autoimmune Product Team for further details and information

Information

Autoimmune thyroid diseases are the most common type of autoimmune diseases. Autoantibodies in blood are directed against different thyroid proteins and impair their functioning. Antibodies against thyroid microsomes, with their main antigen thyroperoxidase (anti-TPO), and antibodies against thyroglobulin (anti-TG) or the thyroid-stimulating hormone receptor (TRAb) are characteristic of autoimmune thyroid diseases.

The most frequent autoimmune thyroid diseases are Graves’ disease and Hashimoto’s thyroiditis. Whereas Graves’ disease is associated with hyperthyroidism, Hashimoto’s thyroiditis manifests as hypothyroidism.

Diagnostic Guidelines

If thyroid disease is suspected, a thyroid function test should be performed to supplement the clinical picture.

A thyroid function test is used to determine the TSH concentration in the blood. An increased TSH level indicates hypothyroidism and a decreased level indicates hyperthyroidism. Additionally, the levels of the free thyroid hormones fT3 and fT4 should be measured in the blood. For the differentiation of an autoimmune thyroid disease from acute (bacterial) or subacute (non-infectious) thyroiditis or a non-autoimmune disorder of the thyroid hormone regulation, the determination of antibodies against thyroid antigens is useful.

Graves’ disease is the most frequent cause of hyperthyroidism in individuals with a sufficient iodide supply. It usually has a sudden onset, with initial symptoms such as palpitations and nervousness. The prevalence of Graves’ disease is approximately 1.5%. The number of affected women is eight times higher than that of men. Graves’ disease is characterized by the continuous stimulation of TSH receptors through the binding of TRAb. They act as TSHR agonists and lead to increased iodide uptake, resulting in thyroid growth and increased thyroid-hormone synthesis and release. Main symptoms are struma, tachycardia and endocrine orbitopathy.

The prevalence of Hashimoto’s thyroiditis is 2% in women and 0.2% in men. In contrast to Graves’ disease, the onset of Hashimoto’s disease is usually clinically inconspicuous and can lead to hypothyroidism after years. The majority of cases develop struma. Typical symptoms are cold intolerance, constipation and fatigue. The underlying cause of the disease is autoimmune lymphocytic infiltration, which leads to T-cell-mediated destruction of the thyroid tissue and thus to reduced production of the thyroid hormones triiodothyronine (T3) and thyroxine (T4) in the long term. The antibodies characteristic of Hashimoto’s thyroiditis are anti-TPO and anti-TG.

Postpartum thyroiditis (PPT) is a de novo autoimmune disease that occurs in approximately 5% to 9% of women within one year of delivery and is associated with high titers of anti-TPO and/or anti-TG. The risk of developing the disease is particularly high if the mothers already exhibited thyroid antibodies or had type 1 diabetes mellitus. The majority of affected women have transient hypothyroidism. But a hyperthyroid phase followed by a hypothyroid phase or isolated thyrotoxicosis can also occur. In 20% to 40%, hypothyroidism persists beyond the postpartum period.

TRAb are the most important serological markers of Graves’ disease, as these antibodies can be detected in almost all untreated patients. The TRAb concentration correlates with the disease activity. In a mild course, TRAb may be in the normal range. In these cases, the detection of anti-TPO can support the diagnosis, as these antibodies are found in 90% and anti-TG in up to 30% of Graves’ disease cases.

In Hashimoto’s thyroiditis, anti-TPO are found in about 95% of patients, anti-TG in 60% to 80% and TRAb in 6% to 12%.

For sufficient differential diagnostics, the overall picture obtained from the investigation of different parameters must be evaluated. In addition to the serological results, the clinical picture and the results of further examinations such as ultrasound examination or scintigraphy must be considered.

Thyroid diseases products

For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter Substrate Species/ Antigen
568 IFA thyroid gland
(MAb + TAb)
thyroid gland monkey
569 IFA thyroid gland (MAb + TAb)
mitochondria (AMA)
thyroid gland
kidney
(2 BIOCHIPs per field)
monkey
rat
570 IFA Polyendocrinopathy Mosaic
thyroid gland (MAb + TAb)
pancreas islets
adrenal cortex
ovarian antigens
Leydig cells
parietal cells (PCA)

thyroid gland (MAb + TAb)
pancreas islets
adrenal cortex
ovarian antigens
Leydig cells
parietal cells (PCA)
6 BIOCHIPs per field:
thyroid gland
pancreas
adrenal gland
ovary
testis
stomach
monkey
monkey
monkey
monkey
monkey
monkey
571 IFA EUROPLUS
thyroid gland (MAb + TAb)
thyroglobulin (TG)
2 BIOCHIPs per field:
thyroid gland
TG BIOCHIPs
monkey
human
572 IFA antibodies against thyroid microsomes
(MAb control)
573 ELISA thyroid peroxidase
(TPO)
antigen-coated
microplate wells
recombinant, expression with
Baculovirus vector in insect cells
574 RIA thyroid peroxidase (TPO)
coated tubes (CT)
antigen-coated
tubes
native thyroid
peroxidase, human
575 RIA thyroid peroxidase (TPO)
precipitation
labelled antigen native thyroid
peroxidase, human
576 RIA thyroid peroxidase (TPO)
magnetic separation
labelled antigen native thyroid
peroxidase, human
577 IFA antibodies against thyroglobulin
(TAb control)
578 ELISA thyroglobulin
(TG)
antigen-coated
microplate wells
native, human
thyroid gland
579 RIA thyroglobulin (TG)
coated tubes (CT); IRMA
antibody-coated
tubes
native
thyroglobulin
580 RIA thyroglobulin (TG)
coated tubes (CT)
antigen-coated
tubes
native thyroglobulin,
human
581 RIA thyroglobulin (TG)
magnetic separation
magnetic separation
labelled antigen
native thyroglobulin,
human
584 RIA TSH receptor
coated tubes (CT)
antigen-coated
tubes
native TSH receptor,
porcine
585 RIA free triiodothyronine (FT3)
coated tubes (CT)
antibody-coated
tubes
triiodothyronine,
human
586 ELISA reverse triiodothyronine (RT3) antibody-coated
microplate wells
587 RIA free thyroxine (FT4)
coated tubes (CT)
antibody-coated
tubes
thyroxine,
human
588 RIA Turbo thyrotropin (TSH)
coated tubes (CT); IRMA
antibody-coated
tubes
thyrotropin,
human
589 RIA alcitonin
coated tubes (CT); IRMA
antibody-coated
tubes
calcitonin,
human
590 ELISA calcitonin antibody-coated
microplate wells
synthetic human calcitonin
Method Parameter Substrate Species/ Antigen
Contact our Autoimmune Product Team for further details and information
Download Our Latest <br/>EUROIMMUN US Product Catalog

Product Catalog

Download Our Latest
EUROIMMUN US Product Catalog

Download The EUROIMMUN US Product Catalog (PDF)

2024 EUROIMMUN US

Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap